MDRX Quote, Financials, Valuation and Earnings

LENZ Therapeutics, Inc. has a net margin of -- compared to Veradigm, Inc.'s net margin of -133.6%. Veradigm, Inc.'s return on equity of -- beat LENZ Therapeutics, Inc.'s return on equity of -29.1%.

Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 20.28%. On the other hand LENZ Therapeutics, Inc. has an analysts' consensus of $53.50 which suggests that it could grow by 91.76%. Given that LENZ Therapeutics, Inc. has higher upside potential than Veradigm, Inc., analysts believe LENZ Therapeutics, Inc. is more attractive than Veradigm, Inc..

Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison LENZ Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENZ Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $1.03 per share. Veradigm, Inc. pays -- of its earnings as a dividend. LENZ Therapeutics, Inc. pays out -- of its earnings as a dividend.

Veradigm, Inc. quarterly revenues are --, which are smaller than LENZ Therapeutics, Inc. quarterly revenues of $12.5M. Veradigm, Inc.'s net income of -- is lower than LENZ Therapeutics, Inc.'s net income of -$16.7M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while LENZ Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.90x versus 44.50x for LENZ Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

LifeMD, Inc. has a net margin of -- compared to Veradigm, Inc.'s net margin of -5.91%. Veradigm, Inc.'s return on equity of -- beat LifeMD, Inc.'s return on equity of --.

Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 20.28%. On the other hand LifeMD, Inc. has an analysts' consensus of $9.25 which suggests that it could grow by 147.99%. Given that LifeMD, Inc. has higher upside potential than Veradigm, Inc., analysts believe LifeMD, Inc. is more attractive than Veradigm, Inc..

Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison LifeMD, Inc. has a beta of 1.363, suggesting its more volatile than the S&P 500 by 36.256%.

Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LifeMD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm, Inc. pays -- of its earnings as a dividend. LifeMD, Inc. pays out 16.59% of its earnings as a dividend. LifeMD, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Veradigm, Inc. quarterly revenues are --, which are smaller than LifeMD, Inc. quarterly revenues of $60.2M. Veradigm, Inc.'s net income of -- is lower than LifeMD, Inc.'s net income of -$3.6M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while LifeMD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.90x versus 0.66x for LifeMD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Streamline Health Solutions, has a net margin of -- compared to Veradigm, Inc.'s net margin of -34.2%. Veradigm, Inc.'s return on equity of -- beat Streamline Health Solutions,'s return on equity of -64.34%.

Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 20.28%. On the other hand Streamline Health Solutions, has an analysts' consensus of $22.50 which suggests that it could fall by -71.91%. Given that Veradigm, Inc. has higher upside potential than Streamline Health Solutions,, analysts believe Veradigm, Inc. is more attractive than Streamline Health Solutions,.

Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison Streamline Health Solutions, has a beta of 2.070, suggesting its more volatile than the S&P 500 by 106.993%.

Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Streamline Health Solutions, offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm, Inc. pays -- of its earnings as a dividend. Streamline Health Solutions, pays out -- of its earnings as a dividend.

Veradigm, Inc. quarterly revenues are --, which are smaller than Streamline Health Solutions, quarterly revenues of $4.8M. Veradigm, Inc.'s net income of -- is lower than Streamline Health Solutions,'s net income of -$1.6M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while Streamline Health Solutions,'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.90x versus 1.18x for Streamline Health Solutions,. Usually stocks with elevated PS ratios are considered overvalued.

TruBridge, Inc. has a net margin of -- compared to Veradigm, Inc.'s net margin of 6.3%. Veradigm, Inc.'s return on equity of -- beat TruBridge, Inc.'s return on equity of 1.61%.

Veradigm, Inc. has a consensus price target of $5.83, signalling upside risk potential of 20.28%. On the other hand TruBridge, Inc. has an analysts' consensus of $22.60 which suggests that it could fall by -4.2%. Given that Veradigm, Inc. has higher upside potential than TruBridge, Inc., analysts believe Veradigm, Inc. is more attractive than TruBridge, Inc..

Veradigm, Inc. has a beta of 0.519, which suggesting that the stock is 48.128% less volatile than S&P 500. In comparison TruBridge, Inc. has a beta of 0.591, suggesting its less volatile than the S&P 500 by 40.93%.

Veradigm, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TruBridge, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Veradigm, Inc. pays -- of its earnings as a dividend. TruBridge, Inc. pays out -- of its earnings as a dividend.

Veradigm, Inc. quarterly revenues are --, which are smaller than TruBridge, Inc. quarterly revenues of $86.1M. Veradigm, Inc.'s net income of -- is lower than TruBridge, Inc.'s net income of $5.4M. Notably, Veradigm, Inc.'s price-to-earnings ratio is -- while TruBridge, Inc.'s PE ratio is 126.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Veradigm, Inc. is 0.90x versus 0.98x for TruBridge, Inc.. Usually stocks with elevated PS ratios are considered overvalued.